Scolari Francesco, Caridi Gianluca, Rampoldi Luca, Tardanico Regina, Izzi Claudia, Pirulli Doroti, Amoroso Antonio, Casari Giorgio, Ghiggeri Gian Marco
Divisione di Nefrologia, Spedali Civili, Brescia, Italy.
Am J Kidney Dis. 2004 Dec;44(6):987-99. doi: 10.1053/j.ajkd.2004.08.021.
The recent discovery of mutations in the uromodulin gene ( UMOD ) in patients with medullary cystic kidney disease type 2 (MCKD2), familial juvenile hyperuricemic nephropathy (FJHN), and glomerulocystic kidney disease (GCKD) provides the opportunity for a revision of pathogenic aspects and puts forth the basis for a renewed classification. This review focuses on clinical, pathological, and cell biology advances in UMOD -related pathological states, including a review of the associated clinical conditions described to date in the literature. Overall, 31 UMOD mutations associated with MCKD2 and FJHN (205 patients) and 1 mutation associated with GCKD (3 patients) have been described, with a cluster at exons 4 and 5. Most are missense mutations causing a cysteine change in uromodulin sequence. No differences in clinical symptoms between carriers of cysteine versus polar residue changes have been observed; clinical phenotypes invariably are linked to classic MCKD2/FJHN. A common motif among all reports is that many overlapping symptoms between MCKD2 and FJHN are present, and a separation between these 2 entities seems unwarranted or redundant. Cell experiments with mutant variants indicated a delay in intracellular maturation and export dynamics, with consequent uromodulin storage within the endoplasmic reticulum (ER). Patchy uromodulin deposits in tubule cells were found by means of immunohistochemistry, and electron microscopy showed dense fibrillar material in the ER. Mass spectrometry showed only unmodified uromodulin in urine of patients with UMOD mutations. Lack of uromodulin function(s) is associated with impairments in tubular function, particularly the urine-concentrating process, determining water depletion and hyperuricemia. Intracellular uromodulin trapping within the ER probably has a major role in determining tubulointerstitial fibrosis and renal failure. We propose the definition of uromodulin storage diseases for conditions with proven UMOD mutations.
近期在2型髓质囊性肾病(MCKD2)、家族性青少年高尿酸血症肾病(FJHN)和肾小球囊性肾病(GCKD)患者中发现了尿调节蛋白基因(UMOD)突变,这为重新审视发病机制提供了契机,并为重新分类奠定了基础。本综述重点关注与UMOD相关病理状态的临床、病理和细胞生物学进展,包括对文献中迄今描述的相关临床病症的综述。总体而言,已描述了31个与MCKD2和FJHN相关的UMOD突变(205例患者)以及1个与GCKD相关的突变(3例患者),这些突变集中在外显子4和5。大多数是错义突变,导致尿调节蛋白序列中的半胱氨酸发生改变。未观察到半胱氨酸改变携带者与极性残基改变携带者在临床症状上的差异;临床表型始终与经典的MCKD2/FJHN相关。所有报告中的一个共同主题是,MCKD2和FJHN之间存在许多重叠症状,将这两个实体区分开来似乎没有必要或多余。对突变变体进行的细胞实验表明,细胞内成熟和输出动力学延迟,导致尿调节蛋白在内质网(ER)中蓄积。通过免疫组织化学在肾小管细胞中发现了散在的尿调节蛋白沉积物,电子显微镜显示内质网中有致密的纤维状物质。质谱分析显示,UMOD突变患者的尿液中只有未修饰的尿调节蛋白。尿调节蛋白功能缺失与肾小管功能受损有关,尤其是尿液浓缩过程,导致水分消耗和高尿酸血症。内质网内细胞内尿调节蛋白截留可能在决定肾小管间质纤维化和肾衰竭方面起主要作用。对于已证实存在UMOD突变的病症,我们建议定义为尿调节蛋白蓄积病。